NO20090171L - Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike - Google Patents

Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike

Info

Publication number
NO20090171L
NO20090171L NO20090171A NO20090171A NO20090171L NO 20090171 L NO20090171 L NO 20090171L NO 20090171 A NO20090171 A NO 20090171A NO 20090171 A NO20090171 A NO 20090171A NO 20090171 L NO20090171 L NO 20090171L
Authority
NO
Norway
Prior art keywords
preparation
salts
processes
pyridines
substituted
Prior art date
Application number
NO20090171A
Other languages
English (en)
Inventor
Karl-Heinz Thierauch
Hans Briem
Ulf Bomer
Stuart Ince
Georg Kettschau
Ingo Hartung
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090109A external-priority patent/EP1867648A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of NO20090171L publication Critical patent/NO20090171L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen vedrører substituerte pyrazolopyridiner ifølge den generelle formel (I) hvor A, B, D, E, Ra, R,,,, R5 og q er som definert i kravene, og salter derav, farmasøytiske preparater som omfatter de substituerte pyrazolo-pyridinforbindelsene, fremgangsmåter for fremstilling av de substituerte pyrazolopyridiner, samt anvendelser derav til fremstilling av et farmasøytisk preparat for behandling av sykdommer med feilregulert karvekst eller av sykdommer som ledsages av feilregulert karvekst, hvor forbindelsene virker effektivt inn på Tie2-signalisering.
NO20090171A 2006-06-13 2009-01-12 Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike NO20090171L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06090109A EP1867648A1 (en) 2006-06-13 2006-06-13 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.
EP07090020 2007-02-15
PCT/EP2007/005432 WO2007144204A1 (en) 2006-06-13 2007-06-12 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them

Publications (1)

Publication Number Publication Date
NO20090171L true NO20090171L (no) 2009-03-12

Family

ID=38445661

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090171A NO20090171L (no) 2006-06-13 2009-01-12 Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike

Country Status (21)

Country Link
US (1) US7846928B2 (no)
EP (1) EP2061790B1 (no)
JP (1) JP5475442B2 (no)
KR (1) KR20090018212A (no)
AR (1) AR061346A1 (no)
AU (1) AU2007260216A1 (no)
BR (1) BRPI0711961A2 (no)
CA (1) CA2654789C (no)
CL (1) CL2007001711A1 (no)
CR (1) CR10505A (no)
EA (1) EA200802407A1 (no)
EC (1) ECSP088963A (no)
ES (1) ES2515117T3 (no)
GT (1) GT200800285A (no)
IL (1) IL195813A0 (no)
MX (1) MX2008015955A (no)
NO (1) NO20090171L (no)
PE (1) PE20080205A1 (no)
TW (1) TW200815438A (no)
UY (1) UY30409A1 (no)
WO (1) WO2007144204A1 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
NZ585063A (en) 2007-11-02 2012-05-25 Vertex Pharma [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
CN102083794A (zh) * 2008-05-05 2011-06-01 安姆根有限公司 作为γ分泌酶调节剂的脲化合物
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JP5689069B2 (ja) 2008-11-20 2015-03-25 ジェネンテック， インコーポレイテッド ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
EP2831072B1 (en) * 2012-03-26 2017-04-19 Arroyo BioSciences L.L.C. Novel sphingosine 1-phosphate receptor antagonists
US20150164910A1 (en) * 2012-06-15 2015-06-18 The Regents Of The University Of Califonia Antiviral compounds and methods of use
WO2017053604A1 (en) 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
BR112020003725A2 (pt) 2017-10-06 2020-11-03 Forma Therapeutics, Inc. inibição da peptidase 30 específica de ubiquitina
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
SI3860989T1 (sl) 2018-10-05 2023-06-30 Forma Therapeutics, Inc. Kondenzirani pirolini,ki delujejo kot zaviralci ubikvitin-specifične proteaze (usp30)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670364B2 (en) * 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
ATE469888T1 (de) * 2003-05-22 2010-06-15 Abbott Lab Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
FR2876691B1 (fr) * 2004-10-18 2006-12-29 Sanofi Aventis Sa Derives de pyridine, leur preparation, leur application en therapeutique
JP5112875B2 (ja) * 2004-10-29 2013-01-09 アボット・ラボラトリーズ 新規なキナーゼ阻害薬
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
EP1683796A1 (en) * 2005-01-24 2006-07-26 Schering Aktiengesellschaft Pyrazolopyridines, their preparation and their medical use
WO2007000241A1 (en) * 2005-06-27 2007-01-04 Sanofi-Aventis Pyrazolopyridine derivatives as inhibitors of beta-adrenergic receptor kinase 1

Also Published As

Publication number Publication date
JP2009539914A (ja) 2009-11-19
IL195813A0 (en) 2009-09-22
CL2007001711A1 (es) 2008-01-04
PE20080205A1 (es) 2008-06-01
CR10505A (es) 2009-03-20
US20080058326A1 (en) 2008-03-06
KR20090018212A (ko) 2009-02-19
TW200815438A (en) 2008-04-01
JP5475442B2 (ja) 2014-04-16
ECSP088963A (es) 2009-01-30
EP2061790B1 (en) 2014-08-13
ES2515117T3 (es) 2014-10-29
US7846928B2 (en) 2010-12-07
AR061346A1 (es) 2008-08-20
UY30409A1 (es) 2008-01-31
AU2007260216A1 (en) 2007-12-21
WO2007144204A1 (en) 2007-12-21
CA2654789A1 (en) 2007-12-21
EA200802407A1 (ru) 2009-06-30
GT200800285A (es) 2009-03-09
EP2061790A1 (en) 2009-05-27
MX2008015955A (es) 2009-01-09
BRPI0711961A2 (pt) 2012-01-17
CA2654789C (en) 2014-08-05

Similar Documents

Publication Publication Date Title
NO20090171L (no) Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike
UA95644C2 (ru) Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний
TW200833690A (en) 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200637860A (en) Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
TW200716654A (en) Sulfoximine-macrocycle compounds and salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing same and uses of same
WO2008106130A3 (en) Tertiary amine substituted peptides useful as inhibitors of hcv replication
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
ATE495743T1 (de) Triazolopyridinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20092476L (no) Antibakterielle polycykliske ureaforbindelser
WO2008067119A3 (en) Novel compounds
TW200606162A (en) Pyrazolopyridine derivatives
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201000615A1 (ru) Производные имидазо[1,2-а]пиридина, применимые в качестве ингибиторов апк (активиноподобной киназы)
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
WO2008155140A8 (en) Alkynylpyrimidines as tie2 kinase inhibitors
NO20085212L (no) Nye pyridinanaloger
DE602008001725D1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5-carbonsäurederivate zur behandlung von diabetes mellitus
WO2009021965A3 (en) Substituted quinoline derivatives as h1 receptor antagonists
ATE433450T1 (de) Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
NO20076448L (no) Novel piperidine carboxylic acid amide derivatives
DK1869038T3 (da) Substituerede 5,6,7,8-tetrahydro-imidazol[1,2-a]pyridin-2-ylamin-forbindelser og deres anvendelse til fremstilling af lægemidler
WO2008074803A3 (en) 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
WO2006066957A3 (en) Sulfonamido-macrocycles as tie2 inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application